Endocrine System Diseases  >>  mitoglitazone (MSDC-0160)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mitoglitazone (MSDC-0160) / Metabolic Solutions
NCT00760578: A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

Completed
2a
86
US
Placebo, Pioglitazone, MSDC-0160 90 mg, MSDC-0160 220 mg
Metabolic Solutions Development Company
Type 2 Diabetes Mellitus
01/09
02/09

Download Options